LRPAP1 antibody (clone AT8G8)
- Known as:
- LRPAP1 (anti-) (clonality AT8G8)
- Catalog number:
- ATGA0321
- Product Quantity:
- 50ul
- Category:
- -
- Supplier:
- ATGen
- Gene target:
- LRPAP1 antibody (clone AT8G8)
Related genes to: LRPAP1 antibody (clone AT8G8)
- Gene:
- LRPAP1 NIH gene
- Name:
- LDL receptor related protein associated protein 1
- Previous symbol:
- A2MRAP, RAP
- Synonyms:
- HBP44
- Chromosome:
- 4p16.3
- Locus Type:
- gene with protein product
- Date approved:
- 1993-07-13
- Date modifiied:
- 2019-04-23
Related products to: LRPAP1 antibody (clone AT8G8)
Related articles to: LRPAP1 antibody (clone AT8G8)
- To characterise proteomic changes associated with depression risk across different follow-up periods and develop predictive models integrating protein and clinical features. - Source: PubMed
Publication date: 2026/06/05
Hui JingniWei WenmingChuyu PanZhao BoyueGou YifanHe DanFeng JinCheng ShiqiangYang XuenaCheng BolunZhang Feng - The low-density lipoprotein receptor-related protein 2 (LRP2) is an endocytic receptor implicated in the homeostasis of multiple organs. While the low-density lipoprotein receptor-related protein-associated protein 1 (LRPAP1) interacts with LRP2, its regulatory role remains elusive. Past studies showed that a single LRPAP1 molecule binds to LRP2 via complement-type repeats. However, many domains of this kind appear unoccupied in LRP2 within the complex. Here, we investigate if multiple LRPAP1 copies could bind the receptor. Using an integrative structural approach, we characterise the human recombinant LRP2 extracellular domain and its complex with LRPAP1, by identifying three additional LRPAP1 binding sites. Notably, two of these sites overlap with ligand-binding regions, suggesting that LRPAP1 may regulate LRP2 ligand-binding activity. Furthermore, we highlight LRPAP1-LRP2 interaction sites unique within the receptor's family and pathogenic LRP2 mutations located at LRP2-LRPAP1 interfaces. Overall, our study redefines the landscape of the LRP2-LRPAP1 interaction, providing insights into its clinical and functional role. - Source: PubMed
Publication date: 2026/04/18
Ramanadane KarthikDi Ianni AlessioGraziadei AndreaTosatto LauraMiele FedericaCoscia Francesca - The aim of this study was to search for human genes potentially involved in the pathogenesis of hepatitis C by multi-network bioinformatics linkage analysis of proteins involved in the stages of hepatitis C virus (HСV) attachment and entry. - Source: PubMed
Publication date: 2025/07/21
Anufrieva E VOstankova Y VDavydenko V SSchemelev A NTotolian A A - The interplay between angiogenesis and the immune system is intricate, with the potential to either enhance or repress the immune response. Angiogenesis-related genes (ARGs) are significant for the development, growth, and immune response of tumors. Understanding their prognostic significance and molecular characteristics in skin melanoma can guide and refine therapeutic strategies. Here, we analyzed the TCGA-SKCM dataset and explored the ARG expression between skin melanoma and normal skin, as well as between primary and metastatic tumors. Kaplan-Meier analyses were conducted to assess the overall, disease-specific, and progression-free survival. Additionally, comprehensive immune profiling was carried out utilizing advanced bioinformatics tools to evaluate immune checkpoint gene expression and immune cell infiltration. Our findings highlighted strong prognostic associations for , , and . Molecular characterization showed a significant upregulation of , , , , , , , , , , and in SKCM compared to that in normal skin. Immune analyses, including Immune Checkpoint Gene Analysis, Immune Infiltration Analysis, Immune Cell Analysis, and Immune Cell Profiling, demonstrated both positive and negative correlations between ARGs expression and immune cell infiltration, emphasizing the multifaceted role of these genes in immune modulation. The study underscores the prognostic relevance of ARGs in skin melanoma and their contribution to tumor immunity. Overall, our findings expand our understanding of melanoma immunogenetics, suggesting the use of angiogenesis-related genes not merely as vascular regulators, but also as immune modulators. - Source: PubMed
Publication date: 2025/08/26
Vladova LatchezaraGeorgakopoulos-Soares IliasZaravinos Apostolos - Ulcerative colitis (UC), a subtype of inflammatory bowel disease (IBD), is a chronic, relapsing inflammatory condition that significantly impairs the patient's quality of life. While biologics have transformed disease management, a substantial number of patients remain unresponsive or lose efficacy over time. Tofacitinib (TOFA), an oral Janus kinase (JAK) inhibitor, introduces a novel therapeutic class of small-molecule drugs with a unique oral administration route, offering enhanced patient convenience and broader accessibility compared to parenterally administered biologics. As the first oral treatment approved for moderate to severe UC in years, TOFA acts by modulating the JAK/STAT pathway, influencing critical inflammatory mediators such as IL-6, IL-17, and IFN-γ. However, response rates are variable and appear dose-dependent, with up to 60% of patients showing inadequate therapeutic outcomes. This review represents the first comprehensive synthesis focused specifically on biomarkers of TOFA response in UC. Drawing on multi-omics data-epigenomics, transcriptomics, proteomics, and cellular profiling, we highlight emerging predictors of responsiveness, including CpG methylation signatures (e.g., and ), transcriptomic regulators (e.g., and ), immune and epithelial cell shifts, and the cationic transporter MATE1. TOFA demonstrates a dual mechanism by modulating immune responses while supporting epithelial barrier restoration. Despite being promising, TOFA's dose-dependent efficacy and interpatient variability underscore the critical need for non-invasive, predictive biomarkers to guide personalized treatment. As the first review of its kind, this work establishes a basis for precision medicine approaches to optimize the clinical utility of TOFA in UC management. - Source: PubMed
Publication date: 2025/07/29
Bizjak AnjaGole BorisJezernik GregorPotočnik UrošGorenjak Mario